Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

McKinsey
Medtronic
AstraZeneca
Express Scripts
Johnson and Johnson
Dow

Last Updated: August 8, 2022

Investigational Drug Information for Ganetespib


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


What is the development status for investigational drug Ganetespib?

Ganetespib is an investigational drug.

There have been 32 clinical trials for Ganetespib. The most recent clinical trial was a Phase 2 trial, which was initiated on April 1st 2013.

The most common disease conditions in clinical trials are Lung Neoplasms, Breast Neoplasms, and Carcinoma, Non-Small-Cell Lung. The leading clinical trial sponsors are Synta Pharmaceuticals Corp., National Cancer Institute (NCI), and Emory University.

There are three hundred and thirty-three US patents protecting this investigational drug and three international patents.

Recent Clinical Trials for Ganetespib
TitleSponsorPhase
European Trial on Enhanced DNA Repair Inhibition in Ovarian CancerEuropean CommissionPhase 2
European Trial on Enhanced DNA Repair Inhibition in Ovarian CancerUniversitaire Ziekenhuizen LeuvenPhase 2
A Pilot Preoperative Trial of Ganetespib With Paclitaxel for Triple-Negative Breast CancerUniversity of ChicagoN/A

See all Ganetespib clinical trials

Clinical Trial Summary for Ganetespib

Top disease conditions for Ganetespib
Top clinical trial sponsors for Ganetespib

See all Ganetespib clinical trials

US Patents for Ganetespib

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Ganetespib See Plans and Pricing Compounds and their methods of use Agios Pharmaceuticals, Inc. (Cambridge, MA) See Plans and Pricing
Ganetespib See Plans and Pricing Pyrrolidinone derivatives as MetAP-2 inhibitors Merck Patent GmbH (Darmstadt, DE) See Plans and Pricing
Ganetespib See Plans and Pricing Bicyclic bromodomain inhibitors Zenith Epigenetics Ltd. (Calgary, AB, CA) See Plans and Pricing
Ganetespib See Plans and Pricing Glutaminase inhibitors and method of use Agios Pharmaceuticals, Inc. (Cambridge, MA) See Plans and Pricing
Ganetespib See Plans and Pricing Constructs targeting AFP peptide/MHC complexes and uses thereof EUREKA THERAPEUTICS, INC. (Emeryville, CA) See Plans and Pricing
Ganetespib See Plans and Pricing Peptidomimetic macrocycles as modulators of MCL-1 AILERON THERAPEUTICS, INC. (Cambridge, MA) See Plans and Pricing
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Ganetespib

Drugname Country Document Number Estimated Expiration Related US Patent
Ganetespib Australia AU2015231053 2034-03-21 See Plans and Pricing
Ganetespib Brazil BR112016021620 2034-03-21 See Plans and Pricing
Ganetespib Canada CA2943339 2034-03-21 See Plans and Pricing
Ganetespib China CN106231900 2034-03-21 See Plans and Pricing
Ganetespib Eurasian Patent Organization EA201691896 2034-03-21 See Plans and Pricing
Ganetespib European Patent Office EP3119199 2034-03-21 See Plans and Pricing
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Medtronic
AstraZeneca
Express Scripts
Johnson and Johnson
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.